P1.13-21 Clinical Efficacy and Safety of Apatinib Combined With EGFR - TKIs in Advanced Non-Small Cell Lung Cancer With EGFR - TKIs Resistance

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.878
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Efficacy of EGFR-TKIs With or Without Angiogenesis Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Journal of Cancer
Oncology
2020English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2018English

P3.01-16 Low Dose Apatinib Combined With EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.13-29 IL-22 Confers Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer Bearing EGFR Gene Mutation and Amplification

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P083 Efficacy of EGFR-TKIs in Patients Harboring EGFR Mutations With Non-Adenocartinoma Histology

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA15.01 Strong PD-L1 Expression Predicts Poor Response and De Novo Resistance to EGFR TKIs Among Non-Small Cell Lung Cancer Patients With EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.13-27 a Randomized Study of Concurrent vs Sequential Alternating EGFR-TKIs and Chemotherapy for Advanced NSCLC With EGFR Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-92 Blood Test Parameters as Prognostic Factors in EGFR-Mutated Non-Small Cell Lung Cancer Treated With TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy